CJC-1295 DAC is a peptide that researchers posit may function similarly to growth hormone-releasing hormone (GHRH), potentially increasing the endogenous production of growth hormone (GH) within the organism. The CJC-1295 DAC peptide is a synthetic 29 amino acid analog of GHRH.(1) It is the shortest functional analog of GHRH that still has the potential capacity to trigger GH release from the somatotroph cells in the pituitary gland. Moreover, 4 of the original 29 amino acids in this fragment are substituted in CJC-1295 DAC, to possibly improve the pharmacokinetics of the peptide and prolong its half-life.
The DAC component is a biochemical complex that may further increase the half-life of the peptide. This phenomenon might be ascribed to the alleged capability of the DAC to bind to proteins present in plasma. More precisely, the DAC component appears to entail the attachment of a lysine derivative, identified as N-epsilon-3-maleimidopropionamide, to the C terminus of CJC-1295 DAC. Integrating this modified amino acid sequence with the DAC component might conceivably enhance the pharmacokinetics of CJC-1295 DAC, extending its half-life to approximately 8 days. Simultaneously, it appears to maintain a significant affinity for GHRH receptors, similar to the affinity exhibited by CJC-1295 without DAC.(2)
This does not imply that CJC without DAC has no relevance or use in present day research. For example, CJC-1295 without DAC & Ipamorelin blend has been studied for its suggested synergistic potential, as combining GHRH analogs with peptides that appear to activate the ghrelin receptors in the pituitary gland. It is also posited to result in greater GH-synthesis response from the somatotroph cells.(3)
